61. 自己免疫性溶血性貧血 Autoimmune hemolytic anemia Clinical trials / Disease details
臨床試験数 : 146 / 薬物数 : 131 - (DrugBank : 59) / 標的遺伝子数 : 28 - 標的パスウェイ数 : 158
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04398459 (ClinicalTrials.gov) | May 1, 2020 | 18/5/2020 | The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia | A Phase II, Multicenter, Open-label Trial to Determine the Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic | Refractory/Relapsed Autoimmune Hemolytic Anemia | Drug: Ibrutinib | Institute of Hematology & Blood Diseases Hospital | NULL | Recruiting | 6 Years | 70 Years | All | 18 | Phase 2 | China |
| 2 | NCT03827603 (ClinicalTrials.gov) | February 21, 2017 | 24/1/2019 | Ibrutinib in Steroid Refractory Autoimmune Hemolytic Anemia | Ibrutinib in Steroid Refractory Autoimmune Hemolytic Anemia: ELaboration of Treatment Approach | AIHA - Warm Autoimmune Hemolytic Anemia | Drug: Ibrutinib | Eugene Nikitin | NULL | Active, not recruiting | 18 Years | N/A | All | 50 | Phase 2 | Russian Federation |